Compile Data Set for Download or QSAR
maximum 50k data
Found 9 Enz. Inhib. hit(s) with Target = 'Kappa-type opioid receptor' and Ligand = 'BDBM50027366'
TargetKappa-type opioid receptor(Cavia porcellus (domestic guinea pig))
Rensselaer Polytechnic Institute

Curated by ChEMBL
LigandPNGBDBM50027366(Ketazocine | US10081602, Example Ketazocine | US10...)
Affinity DataKi:  1nMAssay Description:Displacement of [3H]U69593 form kappa opioid receptor in guinea pig brainMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetKappa-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM50027366(Ketazocine | US10081602, Example Ketazocine | US10...)
Affinity DataKi:  1.30nM ΔG°:  -50.7kJ/mole IC50:  5.60nMpH: 7.5 T: 2°CAssay Description:Competition binding experiments were conducted by incubating membrane protein to equilibrium in triplicate in the presence of a fixed concentration o...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM50027366(Ketazocine | US10081602, Example Ketazocine | US10...)
Affinity DataKi:  1.30nMpH: 7.5Assay Description:The binding affinities of certain compounds of the present invention were evaluated using radioligand binding assays in membranes prepared from CHO-K...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM50027366(Ketazocine | US10081602, Example Ketazocine | US10...)
Affinity DataKi:  1.30nMAssay Description:The binding affinities of certain compounds of the present invention were evaluated using radioligand binding assays in membranes prepared from CHO-K...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM50027366(Ketazocine | US10081602, Example Ketazocine | US10...)
Affinity DataIC50:  5.60nMAssay Description:The binding affinities of certain compounds of the present invention were evaluated using radioligand binding assays in membranes prepared from CHO-K...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM50027366(Ketazocine | US10081602, Example Ketazocine | US10...)
Affinity DataIC50:  5.60nMpH: 7.5Assay Description:The binding affinities of certain compounds of the present invention were evaluated using radioligand binding assays in membranes prepared from CHO-K...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM50027366(Ketazocine | US10081602, Example Ketazocine | US10...)
Affinity DataEC50:  0.550nMAssay Description:Inhibition of cAMP accumulation by select compounds was measured in forskolin-stimulated CHO-K1 cells stably expressing KOR. CHO-K1 cells stably expr...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM50027366(Ketazocine | US10081602, Example Ketazocine | US10...)
Affinity DataEC50:  3.30nMAssay Description:Activity at human cloned kappa opioid receptor expressed in CHO cells by [35S]GTPgammaS binding assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetKappa-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM50027366(Ketazocine | US10081602, Example Ketazocine | US10...)
Affinity DataEC50:  0.550nMAssay Description:Inhibition of cAMP accumulation by select compounds was measured in forskolin-stimulated CHO-K1 cells stably expressing KOR. CHO-K1 cells stably expr...More data for this Ligand-Target Pair
In DepthDetails US Patent